search
Back to results

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Primary Purpose

Opioid Pain Medication

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Tranexamic acid
Aminocaproic acid
Recombinant Human Thrombin
Lidocaine Hydrochloride with Epinephrine
Bupivacaine Hydrochloride with Epinephrine
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid Pain Medication

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 18 or older
  • Any patient undergoing elective hand surgery

Exclusion Criteria:

  • Any patient with a traumatic open wound (only surgically created wounds will be included)
  • History of chronic pain
  • History of narcotic addiction
  • History of recreational drug dependency
  • History of psychiatric pathology
  • Allergy to local anesthetics, recombinant human thrombin or tranexamic acid
  • Any patient receiving a supra/infraclavicular block for anesthesia

Sites / Locations

  • NYU Langone HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Topical lidocaine and bupivacaine alone

Topical lidocaine and bupivacaine with thrombin

Topical lidocaine and bupivacaine with thrombin and tranexamic acid

Topical lidocaine and bupivacaine with thrombin and aminocaproic acid;

Arm Description

In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine

In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin

In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid

In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid

Outcomes

Primary Outcome Measures

Change in Postoperative Pain control
Measured by self-reported level of pain recorded in a daily pain diary made by the researchers from the day of the surgery until post-operative day 14. The levels of pain are scored in the following manner: 1-2 no pain, 3-4 mild pain, 5-6 moderate pain, 7-8 severe pain, 9-10 worst pain imaginable.

Secondary Outcome Measures

Change in the amount of opioid pain medication required postoperatively
Measured by self-reported number of pain pills taken postoperatively until post-operative day 14.

Full Information

First Posted
March 22, 2021
Last Updated
January 3, 2023
Sponsor
NYU Langone Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04814433
Brief Title
Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
Official Title
A Randomized, Single-Blinded, Placebo-Controlled Study Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 24, 2021 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a prospective randomized trial examining the effect of topically combined antifibrinolytics (Tranexamic acid) with local anesthetics in all electively created surgical wound beds in hand surgery to provide long term pain relief and decrease the use of postoperative narcotics.
Detailed Description
The aim of the study is to provide long term pain relief and decrease the use of postoperative narcotics. All treatments are applied topically to the surgical bed prior to closure of the skin. Each of the drugs used in this study are Food and Drug Administration (FDA) approved and routinely used for pain relief. However, the route of administration of the drugs and addition of tranexamic acid or aminocaproic acid is considered off-label (outside of the FDA-approved indications) and therefore investigational.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Pain Medication

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Topical lidocaine and bupivacaine alone
Arm Type
Experimental
Arm Description
In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
Arm Title
Topical lidocaine and bupivacaine with thrombin
Arm Type
Experimental
Arm Description
In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
Arm Title
Topical lidocaine and bupivacaine with thrombin and tranexamic acid
Arm Type
Experimental
Arm Description
In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
Arm Title
Topical lidocaine and bupivacaine with thrombin and aminocaproic acid;
Arm Type
Experimental
Arm Description
In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid
Intervention Type
Drug
Intervention Name(s)
Tranexamic acid
Intervention Description
FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia. Total dose of 500 mg (20 mL) total will be given.
Intervention Type
Drug
Intervention Name(s)
Aminocaproic acid
Intervention Description
FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Total of 1000 mg total will be given.
Intervention Type
Drug
Intervention Name(s)
Recombinant Human Thrombin
Intervention Description
Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient. Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL. For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given
Intervention Type
Drug
Intervention Name(s)
Lidocaine Hydrochloride with Epinephrine
Intervention Description
Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures. Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer. Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Hydrochloride with Epinephrine
Intervention Description
Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures. Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer. Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given
Primary Outcome Measure Information:
Title
Change in Postoperative Pain control
Description
Measured by self-reported level of pain recorded in a daily pain diary made by the researchers from the day of the surgery until post-operative day 14. The levels of pain are scored in the following manner: 1-2 no pain, 3-4 mild pain, 5-6 moderate pain, 7-8 severe pain, 9-10 worst pain imaginable.
Time Frame
Day1 of Surgery until post operative day 14
Secondary Outcome Measure Information:
Title
Change in the amount of opioid pain medication required postoperatively
Description
Measured by self-reported number of pain pills taken postoperatively until post-operative day 14.
Time Frame
Day1 of Surgery until post operative day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 or older Any patient undergoing elective hand surgery Exclusion Criteria: Any patient with a traumatic open wound (only surgically created wounds will be included) History of chronic pain History of narcotic addiction History of recreational drug dependency History of psychiatric pathology Allergy to local anesthetics, recombinant human thrombin or tranexamic acid Any patient receiving a supra/infraclavicular block for anesthesia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Calahan
Phone
929-455-5826
Email
Thomas.Calahan@nyulangone.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Chiu, MD
Organizational Affiliation
NYU Langone Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Calahan
Phone
929-455-5826
Email
thomas.calahan@nyulangone.org
First Name & Middle Initial & Last Name & Degree
David Chiu, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data. Upon reasonable request. Requests should be directed to Thomas.Calahan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

Learn more about this trial

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

We'll reach out to this number within 24 hrs